Antibody Information
General Information of This Antibody
Antibody ID | ANI0WTBOD |
|||||
---|---|---|---|---|---|---|
Antibody Name | 3G10-TG6 |
|||||
Antibody Type | Monoclonal antibody (mAb) |
|||||
Antibody Subtype | Humanized IgG1-kappa |
|||||
Antigen Name | C-X-C chemokine receptor type 4 (CXCR4) |
Antigen Info |
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
3G10-TG6-vc0101 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 61.00% (Day 21) | Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
|
||||
In Vivo Model | Ramos CDX model | ||||
In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 82.80% (Day 27) | Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Mice were treated with a single intravenous dose of the ADCs at 1.5 mg/kg.
|
||||
In Vivo Model | HPB-ALL CDX model | ||||
In Vitro Model | T acute lymphoblastic leukemia | HPB-ALL cells | CVCL_1820 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 92.90% (Day 21) | Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
|
||||
In Vivo Model | Ramos CDX model | ||||
In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.00% (Day 27) | Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Mice were treated with a single intravenous dose of the ADCs at 3 mg/kg.
|
||||
In Vivo Model | HPB-ALL CDX model | ||||
In Vitro Model | T acute lymphoblastic leukemia | HPB-ALL cells | CVCL_1820 | ||
Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.00% (Day 21) | Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
|
||||
In Vivo Model | HPB-ALL CDX model | ||||
In Vitro Model | T acute lymphoblastic leukemia | HPB-ALL cells | CVCL_1820 | ||
Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 21) | Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Mice were treated with a single intravenous dose of the ADCs at 6 mg/kg.
|
||||
In Vivo Model | Ramos CDX model | ||||
In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 |
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.05 nM
|
Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
In Vitro Model | Plasma cell myeloma | MOLP-8 cells | CVCL_2124 | ||
Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.06 nM
|
Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
In Vitro Model | T acute lymphoblastic leukemia | HPB-ALL cells | CVCL_1820 | ||
Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.06 nM
|
Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
In Vitro Model | Adult T acute lymphoblastic leukemia | MOLT-4 cells | CVCL_0013 | ||
Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.14 nM
|
Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
In Vitro Model | Plasma cell myeloma | RPMI-8226 cells | CVCL_0014 | ||
Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.86 nM
|
Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
8.53 nM
|
Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
In Vitro Model | Plasma cell myeloma | MM1.S cells | CVCL_8792 |
3G10-TG6-vcMMAD [Investigative]
Revealed Based on the Cell Line Data
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.90 nM
|
Positive CXCR4 expression (CXCR4+++/++) | ||
Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 |
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.